Akebia Therapeutics (AKBA) Return on Capital Employed Growth (1y) (2015 - 2026)
Akebia Therapeutics (AKBA) Return on Capital Employed Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 333.00 |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -469.00 |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 8.00 |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 220.00 |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 802.00 |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 340.00 |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 573.00 |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | -813.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -813.00 |
| Mar 31, 2026 | 1,535.00 |
| Dec 31, 2025 | 4,928.00 |
| Sep 30, 2025 | 3,153.00 |
| Jun 30, 2025 | 3,095.00 |
| Mar 31, 2025 | 866.00 |
| Dec 31, 2024 | -455.00 |
| Sep 30, 2024 | 837.00 |
| Jun 30, 2024 | 2,074.00 |
| Mar 31, 2024 | -103.00 |
| Dec 31, 2023 | -355.00 |
| Sep 30, 2023 | 1,617.00 |
| Jun 30, 2023 | -248.00 |
| Mar 31, 2023 | 7,326.00 |
| Dec 31, 2022 | 5,694.00 |
| Sep 30, 2022 | 2,005.00 |
| Jun 30, 2022 | 1,446.00 |
| Mar 31, 2022 | -1,110.00 |
| Dec 31, 2021 | -720.00 |
| Sep 30, 2021 | 483.00 |